Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $50

Benzinga Newsdesk www.benzinga.com Positive 65.9%

Neg 0% Neu 0% Pos 65.9%

Wells Fargo analyst Michael Turrin maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $46 to $50.